SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences enters into patent licensing agreement with Takeda Pharmaceutical

18 Jul 2024 Evaluate

Zydus Lifesciences has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company to market the novel Potassium Competitive Acid Blocker (P-CAB) Vonoprazan in India.  The drug will be marketed under the brand name Vault in the country. Vault, a potassium competitive acid blocker (P-CAB), will be used to treat Gastroesophageal Reflux Disease (GERD) and other acid-related disorders. 

Under the terms of this agreement, Zydus will be marketing the drug in India. Vonoprazan is approved by the Drugs Controller General of India (DCG)I for the treatment of adults with reflux esophagitis and other Acid Peptic Disorders (APD). 

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

942.55 3.35 (0.36%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×